Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Raised by Achmea Investment Management B.V.

Achmea Investment Management B.V. boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 49.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 860,894 shares of the company’s stock after buying an additional 286,371 shares during the period. Achmea Investment Management B.V.’s holdings in Teva Pharmaceutical Industries were worth $18,975,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vestcor Inc raised its holdings in Teva Pharmaceutical Industries by 13.4% during the 4th quarter. Vestcor Inc now owns 16,896 shares of the company’s stock worth $372,000 after buying an additional 1,990 shares during the period. Farther Finance Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 45.3% during the 4th quarter. Farther Finance Advisors LLC now owns 6,592 shares of the company’s stock worth $145,000 after buying an additional 2,054 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 1,371.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 9,165 shares of the company’s stock worth $202,000 after buying an additional 8,542 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 1.3% during the 4th quarter. Sequoia Financial Advisors LLC now owns 113,797 shares of the company’s stock worth $2,508,000 after buying an additional 1,417 shares during the period. Finally, HighTower Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 32.3% during the 4th quarter. HighTower Advisors LLC now owns 196,657 shares of the company’s stock worth $4,334,000 after buying an additional 48,052 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Up 2.6 %

Shares of NYSE TEVA opened at $16.53 on Thursday. The stock has a market cap of $18.74 billion, a price-to-earnings ratio of -11.40, a PEG ratio of 1.44 and a beta of 0.82. The business has a 50 day simple moving average of $18.47 and a 200 day simple moving average of $18.32. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on TEVA. Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, March 7th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Bank of America lowered their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.